MA32554B1 - Vaccin contre hpv - Google Patents
Vaccin contre hpvInfo
- Publication number
- MA32554B1 MA32554B1 MA33605A MA33605A MA32554B1 MA 32554 B1 MA32554 B1 MA 32554B1 MA 33605 A MA33605 A MA 33605A MA 33605 A MA33605 A MA 33605A MA 32554 B1 MA32554 B1 MA 32554B1
- Authority
- MA
- Morocco
- Prior art keywords
- dose
- hpv
- vaccine against
- vaccine
- against hpv
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 241000701806 Human papillomavirus Species 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8510108P | 2008-07-31 | 2008-07-31 | |
| US17656109P | 2009-05-08 | 2009-05-08 | |
| PCT/EP2009/059820 WO2010012780A1 (en) | 2008-07-31 | 2009-07-29 | Vaccine against hpv |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA32554B1 true MA32554B1 (fr) | 2011-08-01 |
Family
ID=41139260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA33605A MA32554B1 (fr) | 2008-07-31 | 2011-02-11 | Vaccin contre hpv |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20110189229A1 (enExample) |
| EP (1) | EP2318042B1 (enExample) |
| JP (1) | JP6022159B2 (enExample) |
| KR (1) | KR20110053340A (enExample) |
| CN (1) | CN102159239A (enExample) |
| AU (1) | AU2009275909A1 (enExample) |
| BR (1) | BRPI0916732B1 (enExample) |
| CA (1) | CA2732436C (enExample) |
| CO (1) | CO6341567A2 (enExample) |
| DK (1) | DK2318042T3 (enExample) |
| DO (1) | DOP2011000031A (enExample) |
| EA (1) | EA201170264A1 (enExample) |
| ES (1) | ES2519490T3 (enExample) |
| HR (1) | HRP20141063T1 (enExample) |
| IL (1) | IL210977A0 (enExample) |
| MA (1) | MA32554B1 (enExample) |
| MX (1) | MX2011001218A (enExample) |
| NZ (1) | NZ590919A (enExample) |
| PE (1) | PE20110327A1 (enExample) |
| PL (1) | PL2318042T3 (enExample) |
| PT (1) | PT2318042E (enExample) |
| RS (1) | RS53607B1 (enExample) |
| SI (1) | SI2318042T1 (enExample) |
| SM (1) | SMT201400170B (enExample) |
| WO (1) | WO2010012780A1 (enExample) |
| ZA (1) | ZA201100889B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2768172A1 (en) | 2009-06-25 | 2010-12-29 | Glaxosmithkline Biologicals S.A. | Novel compositions |
| CN102178944A (zh) * | 2010-09-17 | 2011-09-14 | 大连雅立峰生物制药有限公司 | 人乳头瘤病毒16和18型l1蛋白在昆虫细胞中的表达及应用 |
| CN102229660B (zh) * | 2011-05-25 | 2015-04-22 | 厦门大学 | 截短的人乳头瘤病毒33型l1蛋白 |
| KR101559622B1 (ko) * | 2012-07-30 | 2015-10-13 | 중앙대학교 산학협력단 | 인유두종바이러스 바이러스 유사입자의 고효율 정제방법 |
| EP3191505A2 (en) * | 2014-09-11 | 2017-07-19 | Cadila Healthcare Limited | Superior human papilloma virus antigens with superior immunological properties and vaccine containing it |
| US10063211B2 (en) | 2016-02-03 | 2018-08-28 | Qualcomm Incorporated | Compact bypass and decoupling structure for millimeter-wave circuits |
| RU2628693C1 (ru) * | 2016-11-10 | 2017-08-21 | федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "ФНИЦЭМ им. Н.Ф. Гамалеи" Минздрава России) | РЕКОМБИНАНТНЫЙ ГЕН L1HPV16, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pQE-L1/16, БЕЛОК L1HPV16 И ИХ ПРИМЕНЕНИЕ |
| US20210302427A1 (en) * | 2020-03-31 | 2021-09-30 | Shuhari Group, LLC | Secure Immunity Information Transmission System And Network |
| KR20260109890A (ko) * | 2024-01-04 | 2026-07-13 | 사이안백 엘엘씨 | 백신 조성물에 증가된 안정성을 제공하는 개선된 제형 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| EP1732598A4 (en) * | 2003-12-31 | 2009-08-26 | Pharmexa Inc | TRIGGERING CELLULAR IMMUNE RESPONSES TO THE HUMAN PAPILLOVIRUS USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS |
| US7758866B2 (en) * | 2004-06-16 | 2010-07-20 | Glaxosmithkline Biologicals, S.A. | Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52 |
| KR20070029254A (ko) * | 2004-06-16 | 2007-03-13 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Ｈｐｖ 16과 ｈｐｖ 18 및 적어도 ｈｐｖ 31, 45 또는52로부터 선택된 또 다른 ｈｐｖ 유형에 대한 백신 |
| AR054259A1 (es) * | 2005-04-26 | 2007-06-13 | Glaxosmithkline Biolog Sa | Vacuna contra virus de papiloma humano (hpv) |
-
2009
- 2009-07-29 ES ES09781248.1T patent/ES2519490T3/es active Active
- 2009-07-29 AU AU2009275909A patent/AU2009275909A1/en not_active Abandoned
- 2009-07-29 BR BRPI0916732-3A patent/BRPI0916732B1/pt active IP Right Grant
- 2009-07-29 DK DK09781248.1T patent/DK2318042T3/da active
- 2009-07-29 PE PE2011000104A patent/PE20110327A1/es not_active Application Discontinuation
- 2009-07-29 KR KR1020117004436A patent/KR20110053340A/ko not_active Withdrawn
- 2009-07-29 WO PCT/EP2009/059820 patent/WO2010012780A1/en not_active Ceased
- 2009-07-29 PT PT97812481T patent/PT2318042E/pt unknown
- 2009-07-29 CA CA2732436A patent/CA2732436C/en active Active
- 2009-07-29 NZ NZ590919A patent/NZ590919A/xx not_active IP Right Cessation
- 2009-07-29 EP EP09781248.1A patent/EP2318042B1/en active Active
- 2009-07-29 US US13/056,452 patent/US20110189229A1/en not_active Abandoned
- 2009-07-29 CN CN200980135875XA patent/CN102159239A/zh active Pending
- 2009-07-29 SI SI200931047T patent/SI2318042T1/sl unknown
- 2009-07-29 MX MX2011001218A patent/MX2011001218A/es not_active Application Discontinuation
- 2009-07-29 HR HRP20141063AT patent/HRP20141063T1/hr unknown
- 2009-07-29 RS RS20140613A patent/RS53607B1/sr unknown
- 2009-07-29 PL PL09781248T patent/PL2318042T3/pl unknown
- 2009-07-29 EA EA201170264A patent/EA201170264A1/ru unknown
- 2009-07-29 JP JP2011520506A patent/JP6022159B2/ja active Active
-
2011
- 2011-01-28 DO DO2011000031A patent/DOP2011000031A/es unknown
- 2011-01-31 IL IL210977A patent/IL210977A0/en unknown
- 2011-02-03 ZA ZA2011/00889A patent/ZA201100889B/en unknown
- 2011-02-11 MA MA33605A patent/MA32554B1/fr unknown
- 2011-02-23 CO CO11022213A patent/CO6341567A2/es not_active Application Discontinuation
-
2014
- 2014-11-10 SM SM201400170T patent/SMT201400170B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SMT201400170B (it) | 2015-01-15 |
| DK2318042T3 (da) | 2014-11-10 |
| BRPI0916732B1 (pt) | 2021-06-29 |
| CO6341567A2 (es) | 2011-11-21 |
| CA2732436C (en) | 2018-01-16 |
| DOP2011000031A (es) | 2011-02-28 |
| NZ590919A (en) | 2012-10-26 |
| WO2010012780A1 (en) | 2010-02-04 |
| EP2318042B1 (en) | 2014-08-20 |
| KR20110053340A (ko) | 2011-05-20 |
| US20110189229A1 (en) | 2011-08-04 |
| CN102159239A (zh) | 2011-08-17 |
| PL2318042T3 (pl) | 2015-02-27 |
| MX2011001218A (es) | 2011-03-15 |
| AU2009275909A1 (en) | 2010-02-04 |
| JP6022159B2 (ja) | 2016-11-09 |
| BRPI0916732A2 (pt) | 2017-01-31 |
| RS53607B1 (sr) | 2015-04-30 |
| SI2318042T1 (sl) | 2014-12-31 |
| CA2732436A1 (en) | 2010-02-04 |
| EP2318042A1 (en) | 2011-05-11 |
| PT2318042E (pt) | 2014-11-05 |
| JP2011529475A (ja) | 2011-12-08 |
| PE20110327A1 (es) | 2011-06-29 |
| IL210977A0 (en) | 2011-04-28 |
| HRP20141063T1 (hr) | 2015-01-02 |
| ES2519490T3 (es) | 2014-11-07 |
| ZA201100889B (en) | 2012-04-25 |
| EA201170264A1 (ru) | 2011-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ606993A (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
| EA201170264A1 (ru) | Вакцина против hpv | |
| MD4430B1 (ro) | Compoziţii şi metode de tratament al hepatitei virale C | |
| IL209499A (en) | Human monoclonal antibody against influenza a virus, pharmaceutical compositions comprising the same and use thereof as medicaments | |
| WO2018005519A3 (en) | Cancer treatment combinations | |
| EA200802012A1 (ru) | Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением | |
| JP2017524682A5 (enExample) | ||
| WO2015095167A3 (en) | Cancer immunotherapy by delivering class ii mhc antigens using a vlp-replicon | |
| JP2015533376A5 (enExample) | ||
| JP2011529475A5 (enExample) | ||
| EA200800467A1 (ru) | Применение сложных эфиров гидроксибензойной кислоты и аналогов для получения лекарственного средства для предупреждения и лечения вирусной инфекции | |
| ZA202207389B (en) | Improvements in needle-free delivery | |
| HK1225972A1 (zh) | 利用拉喹莫德来延缓亨廷顿氏病的进展 | |
| TW200628182A (en) | Injection device for administering a medication liquid | |
| Kumar et al. | Estimating the cost impact of switching from a vial to a pre-filled syringe mode of administration for the dTaA-IPV-Hib ‘5-In-1’vaccine in infants | |
| NZ584968A (en) | Novel antiretroviral combination comprising ritonavir and atazanavir | |
| TNSN07166A1 (en) | Composition comprising vlp and amyloid-beta peptide | |
| EP1583545A4 (en) | PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF PEPTIDES OF HIV GP41 AND ITS THERAPEUTIC USE | |
| GB2446748A (en) | Vaccine | |
| HRP20151389T1 (hr) | Antivirusni 2,5-dibenzimidazol-5-il-1-fenil-pirolidinderivat | |
| Sattar et al. | Evaluation of the one-year efficacy, safety and glycaemic effects of evolocumab (AMG 145) in 4,802 subjects with, at high risk for, or at low risk for, diabetes mellitus | |
| Lawitz et al. | Efficacy and safety of MK-5172 and MK-8742±rib-avirin in hepatitis C genotype 1 infected patients with cirrhosis or previous null response: Final results of the C-WORTHY Study (Parts A and B): 196 | |
| INfaNTs | BudgeT ImPaCT aNalysIs of CefTaRolINe veRsus lINezolId oR vaNComyCIN oN The ToP of sTaNdaRd TheRaPy IN The TReaTmeNT of ComPlICaTed sKIN aNd sofT TIssues INfeCTIoNs IN RussIaN fedeRaTIoN | |
| MD3121F1 (en) | Method of viral hepatitis B prophylaxis | |
| Kulikov et al. | Budget Impact Analysis of Ceftaroline Versus Linezolid or Vancomycin on the Top of Standard Therapy in the Treatment of Complicated Skin and Soft Tissues Infections in Russian Federation |